Table I.
Characteristics of the included studies.
| Author, year | Country | SC source | Cell type | Study design | Type of animal | Mode of POF induction | Cell administration | Follow-up duration | Outcome | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Elfayomy, et al, 2016 | Egypt | Human | UCMSCs | Case-control study | Female albino Wistar rat | Paclitaxel | 2×106 1 week after chemotherapy | 6 weeks | FSH; E2; antral follicle count | (22) |
| Song et al, 2016 | China | Human | UCMSCs | Case-control study | Female Wistar rat | Cyclophos-phamide | 1×105a 5×104b 2 weeks after chemotherapy | 6 weeks | FSH; E2; antral follicle count | (23) |
| Su et al, 2016 | China | Sprague Dawley rats | ADSCs | Randomized controlled study | Female rat | Tripterygium glycosides | 2×106 retrograde delivery 50 days after chemotherapy | 4 weeks | E2; antral follicle count; pregnancy test | (24) |
| Liu et al, 2016 | China | Human | OGLCs-iPSCs | Case-control study | Female C57BL/6 mouse | Cyclophos-phamide | 5×108 1 week after chemotherapy | 3 weeks | FSH; E2; ovarian weight; atretic follicle count | (12) |
| Zhang, et al, 2015 | China | Human | HAECs | Case-control study | Female C57/BL6 wild-type mouse | Busulfan and cyclophos-phamide | 2×106 1 week after chemotherapya | 4 weeks | Follicle count | (25) |
| Dang et al, 2015 | China | Human | HCMNCs | Randomized controlled study | Female nude mouse | Gr cobalt 60 γ (11)-ray irradiation | 1×108 1 week after radiotherapy | 4 weeks | E2; FSH; primordial follicle count | (26) |
| Lai et al, 2015 | China | Human | EnSCs | Case-control study | Female C57BL/6 wild-type mouse | Busulfan and cyclophos-phamide | 2×106 1 week after chemotherapya | 8 weeks | Pregnancy test | (27) |
| Liu et al, 2014 | China | Human | EnSCs | Case-control study | Female C57BL/6 mouse | Cyclophos-phamide | 1×104 1 week after chemotherapy | 2 weeks | FSH; E2; ovary weight | (28) |
| Kilic et al, 2014 | Turkey | Rats | BMMSCs | Randomized controlled study | Female Wistar albino rat | Cyclophos-phamide | 1.6×106 9 and 16 days after chemotherapy | 17 days | Follicle count | (29) |
| Liu et al, 2014 | China | Rats | BMMSCs | Case-control study | Female Sprague Dawley rat | Cisplatin | 4×106 6 days after chemotherapya | 4 weeks | E2; antral follicles | (30) |
| Lai et al, 2014 | China | Mice | F-SMSCs or M-SMSCs | Case-control study | Female ICR mouse | Busulfan and cyclophos-phamide | 2×106 1 week after chemotherapya | 8 weeks | Pregnancy test | (31) |
| Wang et al, 2013 | China | Human | HAECs | Case-control study | Female C57BL/6 wild-type mouse | Busulfan and cyclophos-phamide | 2×106 1 week after chemotherapya | 8 weeks | Follicle count | (32) |
| Liu et al, 2013 | China | Human | miR-17-3p-iPS | Case-control study | Female C57BL/6 mouse | Chemoablated | 1×103 1 week after chemotherapy | 3 weeks | FSH; E2; ovary weight | (33) |
| Wang et al, 2013 | China | Human | UCMSCs | Randomized controlled study | Female CD1 (ICR) mouse | Cyclophos-phamide | 1×106 15 days after chemotherapya | 1 weeks | Follicle count | (34) |
| Fu et al, 2008 | China | Wistar rats | BMMSCs | Randomized controlled study | Female Wistar rat | Cyclophos-phamide | 2×106 2 weeks after chemotherapy | 8 weeks | FSH; E2; follicle count | (35) |
| Lee et al, 2007 | USA | Mice | BMMSCs | Case-control study | Female C57BL/6 and 129/Sv mouse | Busulfan and cyclophos-phamide | 2–3×107 1 and 8 weeks after chemotherapya | 8 weeks | Follicle count | (36) |
a
Tail intravenous injection
b
in situ. SC, stem cell; UCMSCs, human umbilical cord mesenchymal stem cells; ADSCs, adipose-derived stem cells; OGLCs-iPSCs, ovarian granulosa-like cells derived from human induced pluripotent stem cells; HAECs, human amniotic epithelial cells; HCMNCs, human cord blood mononuclear cells; EnSCs, human endometrial mesenchymal stem cells; BMMSCs, bone marrow derived mesenchymal stem cells; miR-17-3p-iPS, microRNA-17-3p-transfected human induced pluripotent stem cells; F/M-SMSCs, female/male skin-derived mesenchymal stem cells; FSH, follicle-stimulating hormone; E2, estradiol; POI, premature ovarian insufficiency; POF, premature ovarian failure; d, days;.